Therapeutic Effects of Radiolabeled 17-Allylamino-17-Demethoxygeldanamycin on Human H460 Nonsmall-Cell Lung Carcinoma Xenografts in Mice

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 2, 2010, Pages 155-164

  Sun, Jin ^a   Liu, Lu ^a   Jiang, Xinyu ^a   Chen, Daozhen ^a,b   Huang, Ying ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

17 (allylamino) 17 demethoxygeldanamycin (17 AAG); HSP90 inhibitors; Radiolabeling; Targeted radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 ALPHA; KI 67 ANTIGEN; RADIOPHARMACEUTICAL AGENT; TANESPIMYCIN; TANESPIMYCIN I 131; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG UPTAKE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; BENZOQUINONES; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IODINE RADIOISOTOPES; LACTAMS, MACROCYCLIC; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77951944305     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2009.0664     Document Type: Article

References (34)

1. Goetz MP, Toft DO, Ames MM, et al. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003;14:1169.
2. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761.
3. Burrows F, Zhang H, Kamal A. Hsp90 activation and cell cycle regulation. Cell Cycle 2004;3:1530.
4. Prodromou C, Pearl LH. Structure and functional relationships of Hsp90. Curr Cancer Drug Targets 2003;3:301.
5. Walerych D, Kudla G, Gutkowska M, et al. Hsp90 chaperones wild-type p53 tumor suppressor protein. J Biol Chem 2004;279:48836.
6. Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006;13 (suppl 1) : S125.
7. Bagatell R, Whitesell L. Altered Hsp90 function in cancer: A unique therapeutic opportunity. Mol Cancer Ther 2004;3:1021.
8. Banerji U, Walton M, Raynaud F, et al. Pharmacokineticpharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 2005;11 (19pt1) : 7023.
9. Tse AN, Klimstra DS, Gonen M, et al. A phase 1 doseescalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clin Cancer Res 2008;14:6704.
10. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152.
11. Ramalingam SS, Egorin MJ, Ramanathan RK, et al. A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Clin Cancer Res 2008;14:3456.
12. Csermely P, Schnaider T, Soti C, et al. The 90-kDa molecular chaperone family: Structure, function, and clinical applications: A comprehensive review. Pharmacol Ther 1998;79:129.
13. Workman P. Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 2004;10:47.
14. Kamal A, Boehm MF, Burrows FJ. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 2004;10:283.
15. McLaughlin SH, Ventouras LA, Lobbezoo B, et al. Independent ATPase activity of Hsp90 subunits creates a flexible assembly platform. J Mol Biol 2004;344:813.
16. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407.
17. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003;3:213.
18. Tweedle MF. Peptide-targeted diagnostics and radiotherapeutics. Acc Chem Res 2009;42:958.
19. Wahl RL. Tositumomab and (131) I therapy in non-Hodgkin's lymphoma. J Nucl Med 2005;46 Suppl 1:128S.
20. Chang JW, Asamura H, Kawachi R, et al. Gender difference in survival of resected non-small cell lung cancer: histologyrelated phenomenon? J Thorac Cardiovasc Surg 2009;137:807.
21. Shimamura T, Shapiro GI. Heat shock protein 90 inhibition in lung cancer. J Thorac Oncol 2008;3: S152.
22. Workman P, Powers MV. Chaperoning cell death: A critical dual role for Hsp90 in small-cell lung cancer. Nat Chem Biol 2007;3:455.
23. Daozhen C, Lu L, Min Y, et al. Synthesis of (131) I-labeled-[(131) I]iodo-17-allylamino-17-demethoxy geldanamycin ([(131) I]iodo-17-AAG) and its biodistribution in mice. Cancer Biother Radiopharm 2007;22:607.
24. Braga-Basaria M, Hardy E, Gottfried R, et al. 17-Allylamino-17- demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels. J Clin Endocrinol Metab 2004;89:2982.
25. Clarke PA, Hostein I, Banerji U, et al. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 2000;19:4125.
26. Burger AM, Fiebig HH, Stinson SF, et al. 17-(Allylamino)-17- demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 2004;15:377.
27. Gress TM, Mü ller-Pillasch F, Weber C, et al. Differential expression of heat shock proteins in pancreatic carcinoma. Cancer Res 1994;54:547.
28. Jalava P, Kuopio T, Juntti-Patinen L, et al. Ki67 immunohistochemistry: A valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology 2006;48:674.
29. Solit DB, Osman I, Polsky D, et al. Phase II trial of 17-allylamino-17-demethoxygeldanamycin inpatients with metastatic melanoma. Clin Cancer Res 2008;14:8302.
30. Heath EI, Hillman DW, Vaishampayan U, et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2008;14:7940.
31. Ramanathan RK, Egorin MJ, Eiseman JL, et al. Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res 2007;13:1769.
32. Solit DB, Ivy SP, Kopil C, et al. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007;13:1775.
33. Supko JG, Hickman RL, Grever MR, et al. Preclinical pharmacologic evaluation of Cancer Chemother Pharmacol 1995;36:305.
34. Gallegos Ruiz MI, Floor K, Roepman P, et al. Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One 2008;3: e0001722.